GlassScriptPhysician profile
Grady J Stephens
NPI 1477624716
$1,437.16
in general payments reported to CMS, 2019-2025
31 companies · $107 in 2025
The $107 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $362 · 2020: $48.18 · 2021: $447 · 2022: $185 · 2023: $177 · 2024: $110 · 2025: $107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $394.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $394.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Davol INC. | $302.73 | 2019-2021 | |
| Abbvie INC. | $143.75 | 2019-2022 | |
| Heron Therapeutics, INC. | $123.52 | 2021 | |
| Boston Scientific Corporation | $119.18 | 2019-2025 | Tria Firm, Watchman Access System, Watchman Flx |
| Medtronic, INC. | $110.98 | 2021-2025 | Endoflip |
| Merck Sharp & Dohme LLC | $66.57 | 2019-2023 | Dificid |
| Mallinckrodt Hospital Products INC. | $56.84 | 2021 | |
| Daiichi Sankyo INC. | $41.67 | 2021-2022 | |
| Conmed Corporation | $39.20 | 2021 | |
| Urogen Pharma, INC. | $31.68 | 2025 | |
| Intercept Pharmaceuticals, INC. | $31.35 | 2024-2025 | |
| Biom'Up France Sas | $29.09 | 2020 | |
| Polynovo North America LLC | $28.29 | 2024 | Novosorb Btm |
| Nestle Healthcare Nutrition INC. | $28.13 | 2022-2023 | |
| Ethicon US, LLC | $27.24 | 2019-2025 | Echelon Flex, Contour |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $26.67 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.57 | 2022 | |
| Genzyme Corporation | $16.82 | 2023 | |
| Ardelyx, INC. | $16.51 | 2024 | Ibsrela |
| E.R. Squibb & Sons, L.L.C. | $16.36 | 2021 | |
| Redhill Biopharma INC. | $16.23 | 2022 | |
| Smith+Nephew, INC. | $15.64 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $15.54 | 2024 | |
| Novartis Pharmaceuticals Corporation | $15.03 | 2023 | |
| Lilly USA, LLC | $14.55 | 2024 | Omvoh |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.44 | 2022 | |
| Novo Nordisk INC | $13.92 | 2019 | |
| Olympus America INC. | $13.61 | 2025 | Endoclot Phs |
| Shire North American Group INC | $12.80 | 2019 | |
| Vivus LLC | $11.28 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $10.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grady Stephens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.